Clinical Trials Logo

Clinical Trial Summary

The study consists of a Phase1b lead-in portion to determine the maximum tolerated dose (MTD) of OMP-59R5 (tarextumab) in combination with etoposide (EP) for 6 cycles followed a Phase 2, multi center, randomized, placebo-controlled portion comparing the efficacy and safety of OMP-59R5 in combination with EP for 6 cycles followed by single agent OMP-59R5 relative to EP alone for 6 cycles in subjects receiving first-line therapy for extensive stage small cell lung cancer.


Clinical Trial Description

The Phase 1b lead-in portion of the study was conducted to determine the MTD of OMP-59R5 administered along with EP. The Phase 2 portion of the study was multi-center, randomized, and placebo-controlled. Subjects who qualified for enrollment into the Phase 2 portion of the study were randomized in a 1:1 ratio to receive study treatment of tarextumab along with EP (Arm A) or placebo along with EP (Arm B). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01859741
Study type Interventional
Source Mereo BioPharma
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date January 7, 2012
Completion date May 8, 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03223155 - Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer Phase 1
Recruiting NCT04056247 - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments